According to a recent LinkedIn post from One Biosciences, the company has been recognized with the Diagnostics Trophy at the 2026 Trophées de la HealthTech organized by France Biotech. The post credits the achievement to its internal team, partners, and patients, and acknowledges other diagnostics peers BeLiver, Imagine Eyes, and METHYS Dx.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The recognition suggests growing visibility for One Biosciences within the French and European healthtech ecosystem, particularly in medical diagnostics and single-cell technologies. For investors, such an award could indicate external validation of the company’s technology and positioning, potentially supporting future fundraising efforts, partnership discussions, and talent attraction in a competitive diagnostics market.